Flagship @ JPM 2024
Watch discussions from the Flagship Studio at the 2024 J.P. Morgan Healthcare Conference in San Francisco.
Highlights from JPM 2024
Check out highlights from our studio at the 2024 J.P. Morgan Healthcare Conference.
Read Flagship's 2024 Annual Letter by Founder & CEO Noubar Afeyan
PANEL DISCUSSIONS FROM THE FLAGSHIP STUDIO @ JPM
CEO CHATS FROM THE FLAGSHIP STUDIO @ JPM
2024 CEO Chat: Margo Georgiadis, Montai Therapeutics
2024 CEO Chat: Mike Nally, Generate:Biomedicines
2024 CEO Chat: Steve Harr, Sana Biotechnology
2024 CEO Chat: Lovisa Afzelius, Metaphore Biotechnologies
2024 CEO Chat: Guillaume Pfefer, Sail Biomedicines
2024 CEO Chat: John Lepore, ProFound™ Therapeutics
CEO CHATS FROM THE FLAGSHIP STUDIO @ JPM
CEO CHATS FROM THE FLAGSHIP STUDIO @ JPM
JPM 2024 Calendar
In Person -
In Person + Livestream -
JPM Conference Presentation -
External Event -
Monday, 1/8
The event will feature Frances Arnold, Nobel Laureate, Generate Biomedicines board member, and Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology; Sue Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation; Cynthia Patton, General Counsel and Secretary of Tessera; and ĢƵAPP Senior Partner Justine Levin-Allerhand.
At a time when companies increasingly recognize that diversity drives resilience, innovation, and success, our featured speakers will reflect on their own experiences and discuss where they see opportunities for impact through board engagement.
Flagship CEO & Founder Noubar Afeyan shares his outlook for 2024 in a discussion with Endpoints ĢƵAPP' Executive Editor Drew Armstrong.
CEO Chat: Fabrice Chouraqui, Cellarity
JPM Conference Presentation: Moderna
Advances in genetics, machine learning, and human biology are deepening our ability to find associations between patients’ biology and disease pathways, opening up entirely new frontiers for therapeutic intervention. Redefining patient populations based on shared biology offers the opportunity to dramatically scale the creation of new medicines and places the treatment of rare and ultra-rare diseases within reach. At the same time, using the power of genetics to drive small molecule drug discovery has, for the first time, created new ways to treat common diseases with a level of precision that, for the last two decades, has been reserved for rare diseases. Join Christopher Austin, CEO of Vesalius Therapeutics and CEO-Partner, ĢƵAPP, Jason Park, CEO of Empress Therapeutics and Operating Partner, ĢƵAPP, and Michelle Werner, CEO of Alltrna and CEO-Partner, ĢƵAPP will join Robert Plenge, Executive Vice President, Chief Research Officer, Head of Research, Bristol Myers Squibb to discuss the opportunities for bioplatforms to dramatically scale the creation of new medicines and put the treatment of rare and ultra-rare diseases within reach while also finding novel ways to treat common diseases with a level of precision that, for the last two decades, has been reserved for rare diseases.
Tuesday, 1/9
Women trailblazers are transforming business and together, building the next generation of leaders through mentorship and sharing of hard-earned wisdoms gleaned from years of career experiences. Drawing inspiration from the book, “Women Mean Business,” which launched earlier this year, join us for an intimate gathering of women leaders in tech and biotech as we bring this important conversation into the biopharma realm.
Hear extraordinary women leaders Margo Georgiadis, Co-Founder & CEO of Montai and ĢƵAPP CEO-Partner; Cindy Kent, former Chief Operating Officer of Everly Health; Edie Fraser, Chair of the Women Business Collaborative; and Audrey Greenberg, Co-Founder & CBO of the Center for Breakthrough Medicines, in conversation with Christine Heenan, ĢƵAPP Chief Communications Officer & Executive Partner, discussing the most valuable insights that have advanced their careers, the behaviors that sparked innovation and drive, and the dynamics of leadership today that will influence the women leaders of tomorrow.
JPM Conference Presentation: Sana
Charlotte Allerton, Head of Discovery and Early Development at Pfizer joins Paul Biondi, Flagship Executive Partner and President of Pioneering Medicines, for a discussion about pioneering partnerships that leverage capabilities from across the biopharma industry to develop potentially transformational therapeutics, including the strategic alliance between Pfizer and ĢƵAPP.
JPM Conference Presentation: Denali
JPM Conference Presentation: Sail
Fabrice Chouraqui, CEO of Cellarity, and Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub, join Paul Biondi, Flagship Executive Partner and President of Pioneering Medicines, for a discussion about the recently research collaboration between the three companies to unlock a new therapy for Metabolic Steatohepatitis (MASH), for which there are no currently approved treatments.
Join Professor Tan Sze Wee, Assistant Chief Executive, A*STAR’s Biomedical Research Council, and Professor Lucy Chappell, CEO of the UK National Institute for Health Research, in conversation with Flagship Chair of Asia Pacific and Strategic Advisor, ĢƵAPP, André Andonian, for a discussion about how connecting life sciences ecosystems around the globe can unlock opportunities for innovation and value creation by building on our complementary strengths.
Wednesday, 1/10
With the explosion of different modalities and the incredible speed and potential of the AI/ML revolution, partnerships between platform companies and larger pharma are more critical than ever to accelerate drug development. John Lepore, CEO of ProFound Therapeutics and CEO-Partner, ĢƵAPP, Mike Nally, CEO of Generate:Biomedicines and CEO-Partner, ĢƵAPP, and Luciano Rossetti, Chief Medical Officer, ĢƵAPP and Head of Research & Development, Pioneering Medicines will join Amanda Kay, Chief Business Development Officer and Senior Partner, ĢƵAPP to discuss the opportunity that Flagship’s innovative bioplatforms offer in terms of novel partnerships with pharma to bring about new therapeutics.
JPM Conference Presentation: Seres
JPM Conference Presentation: Generate:Biomedicines
CEO Chat: Volker Herrmann, Sonata
CEO Chat: Guillaume Pfefer, Sail
ĢƵAPP Founder and CEO Noubar Afeyan sits down with Marc Casper, CEO of Thermo Fisher Scientific, for a conversation on macroeconomic trends, global market dynamics, and the future of enabling technologies in powering biotech and creating novel therapies.
Read more on the recently announced partnership between Thermo Fisher and Flagship to develop and commercially scale multiproduct platforms on an accelerated basis.
Mahesh Karande, President & CEO of Omega Therapeutics, and Uli Stilz, Head of Novo Nordisk’s Bio Innovation Hub, join Luciano Rossetti, Chief Medical Officer, ĢƵAPP and Head of Research & Development, Pioneering Medicines, for a discussion about the recently announced research collaboration between the three companies to develop a novel therapeutic for obesity management.
Last year was a landmark year in the history of technology with the explosive rise of generative AI. While the application of AI and machine learning in the life sciences is not new, the emergence of increasingly powerful generative AI models has unlocked new drivers of R&D innovation and economic productivity gains in our industry.
Join Anthony Costa, Global Lead, Life Sciences Alliances, NVIDIA; Margo Georgiadis, Co-Founder and CEO of Montai Health and CEO-Partner, ĢƵAPP; and Kathleen Sullivan, Senior Director, Microsoft Health Futures, for a conversation moderated by Marcello Damiani, Senior Partner, ĢƵAPP, reflecting on the learnings these leaders have gleaned one year into the generative AI era and the implications on the future of capital investment, talent, and value creation in the life sciences.